



Drug Prior Authorization Committee Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
April 18, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[* Click HERE for Meeting Documents *](#)

<u>Committee Members Present</u>	<u>MO HealthNet Staff Present</u>	<u>Contractors Present</u>
Chris Brown, RPh. J.K. Sturgeon, PharmD, BCPS James Krings, MD, MSc Laura Kingsley, PharmD, Chair Maya Moody, DO, FAAP Morgan Sperry, PharmD Nicole Tran, PharmD Rashmi Srivastava, MD Ricky Ogden Jr, PharmD	Angela Wilson, Pharmacy Operations Manager Carmen Burton, Pharmacy Support Assistant Connie Sutter, Fiscal Manager Elizabeth Short, Program Development Specialist Elizabeth Sissom, RN, Clinical Review Nurse Joshua Moore, PharmD, Director of Pharmacy Danielle Dodd, Special Counsel Lisa Smith, Pharmacy RFP Coordinator Mark Roaseau, R.Ph., Clinical Pharmacist Nikki Ashley, Pharmacy Program Specialist Olivia Rush, PharmD, Program Integrity Pharmacist Timothy Kling, MD, Acting Medical Director Somia Hamed, UMKC Pharmacy Student Ambra Stotler-Bauda, Benefit Program Senior Specialist	Amanda Williams, PharmD, RPh, GWT Ashley Lytton, RN, BSN, Wipro Chelsea Pendleton, RN, BSN, Wipro Jennifer Colozza, PharmD, Conduent John Crowley, PharmD, BCPS, CPPS, Conduent Karen Powell, PharmD, MS, GWT LeAnna Kirsch, RN, Wipro Lokendra Upadhyay, PharmD, Conduent Lynn Morsches, PharmD, Conduent Mandy Nilges, RN, Wipro Megan Fast, PharmD, GWT Paul Fung, PharmD, MHA Conduent Sandy Kapur, PharmD, GWT Serena Barden, PharmD, BCPS, GWT Vicki Revel, PharmD, GWT
<u>Committee Members Absent</u>		
Angeline Stanislaus, MD Matthew Stinson, MD Nadim Kanafani, MD, MPH		

Others Present:

Angela Hailes

Audrey Rattan

Brian Strickland

Clemice Hurst

Cody Gerber

Daphne Ni

Dennis Murphy

Ed Paiewonsky

Emma Andelson

Folger Tuggle

Gary

Heather FremI

Jemela Williams

Jenny Carrell

John Bullard

Jomy Joseph

Karen Malamut

Keith Gulley

Kevin Mann

Kim Witte

Kurt Hendrickson

Larry Palmisano

Lee Ward

Mara Ward

Marc Parker

Matt Baker

Megan Kricsfeld

Melissa Basil

Michele Shirley

Miranda Anaya

Nancy Mosier

Nancy N

Paul Ford

Richie

Ricki Roberson

Rob Kilo

Sara Gao

Sara Hovland

Sean Jones

Shauna Williams

Steve Patterson

Thomas Yelle

Waleed Al-Homoud

Zach Thomas

<p>Welcome, Announcements and Introductions</p>	<p>Laura Kingsley, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, called the meeting to order, introduced himself along with Ricki Ogden Nadim Kanafani, Rashmi Srivastava, Chris Brown, the newest Committee members, Somia Hamed, MHD's pharmacy student and facilitated the meeting on behalf of the MO HealthNet Division. Morgan Sperry introduced Miranda Anaya.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the December meeting.</p> <p>Decision: The Committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - February 2023 Enrollees and Expenditures - July 2022 – February 2023 Expenditures by Service - FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures - February 2023 Medicaid Expansion Participants, Expenditures, and Claim Count - FY19 to FY23 Mavyret Expenditures - CY2023 Per User Per Month Drug Claim Reimbursement - March 2023 Top Ten Reimbursed Drugs - March 2023 Top Ten Reimbursed Drugs for Children 0-17 - Additional updates were provided on: <ul style="list-style-type: none"> o Clinical Initiatives: <ul style="list-style-type: none"> ▪ Project Hep Cure – selected to receive the 2022 Governor's Award for Quality and Productivity in the category of Innovation ▪ 15 Day Psychotropics Edit retirement ▪ Decreasing unnecessary faxes ▪ CGM Edit – increased look back for insulin ▪ DUR messaging o Reminder that pharmacists attending the meeting are eligible for continuing education o Current and Future Challenges – Drug Pricing o Accelerated approval pipeline products and cost to the state o Autofill regulation

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Committee for discussion and action. - Committee asked MHD to: <ul style="list-style-type: none"> o Revisit the criteria for Ermeza to either allow for an age bypass (i.e., <10 years of age) or complete a fiscal analysis to determine which of the recently approved levothyroxine liquids would be the most appropriate for step through criteria. o Review the placement of Leuprolide 22.5mg vial - Public comment provided by: <ul style="list-style-type: none"> o Matt Baker with Axsome Therapeutics on Auvelity <p>Decision: The Committee voted to accept the presented new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review	
<p style="text-align: center;">Clinical & Fiscal Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Committee which included: <ul style="list-style-type: none"> o Acne or Rosacea, Select Topical Agents o Fabry Disease o Givlaari o Imcivree o Isturisa o Megestrol o Nulibry o Oxervate o Oxlumo o Scenesse o Sickle Cell Disease o Spravato o Systemic Antifungals o Tavneos o Voxzogo o Zokinvy o Zulresso - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Ed Palewronsky with Alnylam Pharmaceuticals on Givlaari o Cody Gerber with Rhythm Pharmaceuticals on Imcivree o Mara Ward with Recordati Rare Disease on Isturisa o Ed Palewronsky with Alnylam Pharmaceuticals on Oxlumo yielded time back o Jemela Williams, Participant Advocate on Sickle Cell Disease o Larry Palmisano with Amgen on Tavneos <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions, recommending Givlaari be sent back to the Rare Disease Advisory Council for further review.</p>

<p align="center">Hemgenix Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Tzield Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Preferred Drug List Edit Review</p>	
<p align="center">Preferred Drug Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Committee which included: <ul style="list-style-type: none"> o Actinic Keratosis Agents, Topical o Androgenic Agents o Antibiotics, Inhaled o Anticholinergics, LABA Combinations o Anticholinergics, Short Acting and Combinations Inhaled o Antifungals, Topical o Antihistamines & Antihistamine/Decongestant Combinations, 2nd Generation o Antihistamines, Intranasal o Antiparasitics, Topical o Antivirals, Herpes Oral o Benzoyl Peroxide/Antibiotic Combinations <ul style="list-style-type: none"> ▪ Committee asked MHD to review coverage of single ingredient benzoyl peroxide products o Beta Adrenergic Agents, Nebulized o Beta Adrenergic Agents, Short Acting o Corticosteroids, Ophthalmic Soft o Corticosteroids, Oral Inhaled o Corticosteroids, Topical

	<ul style="list-style-type: none"> ○ Cough/Cold Preparations ○ Fluoroquinolones, Ophthalmic ○ Fluoroquinolones, Otic ○ Hepatitis C Agents ○ Leukotriene Receptor Modifiers ○ Mast Cell Stabilizers, Ophthalmic ○ NSAIDs, Ophthalmic ○ Pancreatic Enzymes ○ Retinoids, Topical - Public comment provided by: <ul style="list-style-type: none"> ○ Heather Freml with Abbvie on Mavyret yielded time back <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Anticholinergics, Long Acting Inhaled	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Antifungals, Oral	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Antihistamines, Ophthalmic</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Antivirals, Topical</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Beta Adrenergic Agents, Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Corticosteroids & Rhinitis Agents, Intranasal</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Epinephrine Agents, Self-Injectable</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Committee asked about the process when supply chain issues appear <ul style="list-style-type: none"> o MHD watches market availability weekly and adjusts criteria and placement accordingly - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

Glaucoma Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Inflammatory Bowel Disease Agents, Oral	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Inflammatory Bowel Disease Agents, Rectal	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Other Business	
Program Utilization Information – Conduent Update	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 2nd Quarter SFY23 (October, November, December) - Top 25 Drugs by Paid Number 2nd Quarter SFY23 (October, November, December) - Call Center Helpdesk Status Report February 2023 - SmartPA Transparency Report
Adjournment	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p>

NEXT MEETING: Tuesday, April 18, 2023
615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for April 18, 2022

	<u>Action Item</u>							
<u>Board Member</u>	December Meeting Minutes	New Drug Review	Block Vote for Clinical and Fiscal Edits, No Annual Changes	Block Vote for Clinical and Fiscal Edits, Annual Changes	Block Vote for Preferred Drug List Edits, No Annual Changes	Block Vote for Preferred Drug List Edits, Annual Changes	Closing	Adjournment
Angeline Stanislaus	A	A	A	A	A	A	A	A
Chris Brown	Y	Y	Y	Y	Y	Y	Y	Y
J.K. Sturgeon	Y	Y	Y	Y	Y	Y	Y	Y
James Krings	Y	Y	Y	Y	Y	Y	Y	Y
Laura Kingsley	Y	Y	Y	Y	Y	Y	Y	Y
Matthew Stinson	A	A	A	A	A	A	Y	Y
Maya Moody	A	SY	MY	SY	Y	MY	Y	MY
Morgan Sperry	MY	MY	SY	MY	MY	Y	MY	Y
Nadim Kanafani	A	A	A	A	A	A	A	A
Nicole Tran	Y	Y	Y	Y	Y	Y	Y	Y
Rashmi Srivastava	Y	Y	Y	Y	Y	SY	SY	Y
Ricky Ogden	SY	A	A	Y	SY	A	Y	SY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain